HC Wainwright Reaffirms “Buy” Rating for Axovant Sciences Ltd. (AXON)
Several other brokerages have also weighed in on AXON. JMP Securities reaffirmed an outperform rating and issued a $36.00 target price on shares of Axovant Sciences in a research report on Tuesday, August 16th. Zacks Investment Research upgraded Axovant Sciences from a hold rating to a buy rating and set a $17.00 price target for the company in a report on Monday, August 8th. Jefferies Group reiterated a buy rating and issued a $31.00 price target on shares of Axovant Sciences in a report on Monday, September 26th. Robert W. Baird reiterated an outperform rating and issued a $29.00 price target on shares of Axovant Sciences in a report on Friday, September 23rd. Finally, Evercore ISI reiterated a buy rating and issued a $29.00 price target on shares of Axovant Sciences in a report on Friday, September 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. Axovant Sciences has an average rating of Buy and an average target price of $26.33.
Shares of Axovant Sciences (NYSE:AXON) opened at 13.58 on Tuesday. Axovant Sciences has a one year low of $8.86 and a one year high of $21.30. The stock’s market capitalization is $1.35 billion. The firm’s 50-day moving average price is $13.31 and its 200-day moving average price is $13.76.
Axovant Sciences (NYSE:AXON) last issued its earnings results on Monday, August 15th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.02. Equities research analysts anticipate that Axovant Sciences will post ($1.68) EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. Janus Capital Management LLC increased its stake in shares of Axovant Sciences by 0.6% in the second quarter. Janus Capital Management LLC now owns 4,649,151 shares of the company’s stock valued at $59,694,000 after buying an additional 28,512 shares in the last quarter. Franklin Resources Inc. increased its position in Axovant Sciences by 5.9% in the second quarter. Franklin Resources Inc. now owns 1,270,682 shares of the company’s stock worth $16,316,000 after buying an additional 70,900 shares during the period. BlackRock Fund Advisors increased its position in Axovant Sciences by 7.5% in the third quarter. BlackRock Fund Advisors now owns 617,570 shares of the company’s stock worth $8,646,000 after buying an additional 43,320 shares during the period. Ghost Tree Capital LLC purchased a new position in Axovant Sciences during the second quarter worth approximately $7,383,000. Finally, Citadel Advisors LLC increased its position in Axovant Sciences by 850.3% in the second quarter. Citadel Advisors LLC now owns 572,679 shares of the company’s stock worth $7,353,000 after buying an additional 512,413 shares during the period. Institutional investors own 29.43% of the company’s stock.
About Axovant Sciences
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Stock Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related stocks with our FREE daily email newsletter.